剂量调整依诺肝素用于住院癌症患者血栓预防:一项随机双盲多中心2期试验
研究纳入50例根据Padua风险评分高危的住院活动性癌症患者,随机接受固定剂量依诺肝素(40 mg每日)或体重调整依诺肝素(1 mg/kg每日)。两组均无大出血或症状性静脉血栓栓塞;体重调整组仅1例偶发肺栓塞。固定剂量组后续超声监测的深静脉血栓累积发生率为22%(90%二项置信区间0%-51.3%)。
要点
- 高危住院癌症患者中无症状静脉血栓栓塞发生率高。
- 体重调整低分子量肝素血栓预防可行且耐受良好。
- 两组均无大出血或症状性静脉血栓栓塞事件。
核心结论
- 该2期试验证实高危住院癌症患者无症状静脉血栓栓塞发生率高,体重调整低分子量肝素血栓预防可行且耐受良好。
研究设计与样本
- 随机、双盲、多中心2期试验,纳入50例根据Padua风险评分高危的住院活动性癌症患者。
- 患者随机分配至固定剂量依诺肝素(40 mg每日)组或体重调整依诺肝素(1 mg/kg每日)组,住院期间给药。
- 主要目标为评估剂量调整依诺肝素的安全性和固定剂量依诺肝素的静脉血栓栓塞发生率。
- 第14天进行盲法临床评估,固定剂量依诺肝素组随后接受双下肢超声检查。
- 试验注册号NCT02706249。
主要发现
- 体重调整依诺肝素组患者中位体重为76 kg(范围60.9-124.5 kg)。
- 两组均无大出血或症状性静脉血栓栓塞。
- 盲法临床评估完成时,体重调整组仅1例偶发肺栓塞。
- 固定剂量依诺肝素组后续接受监测超声,深静脉血栓累积发生率为22%(90%二项置信区间0%-51.3%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hospitalized patients with cancer are at an increased risk of developing venous thromboembolism (VTE). The recommendation for routine pharmacologic thromboprophylaxis in hospitalized patients with cancer to prevent VTE is based on extrapolation of results from noncancer cohorts. There are limited data to support the efficacy and safety of fixed-dose low-molecular-weight heparin (LMWH) regimens in high-risk hospitalized patients with cancer. We conducted a randomized, double-blinded, phase 2 trial in hospitalized patients with active cancer at high risk of developing VTE based on Padua risk score. Patients were randomly assigned to fixed-dose enoxaparin (40 mg daily) vs weight-adjusted enoxaparin (1 mg/kg daily) during hospitalization. The primary objectives were to evaluate the safety of dose-adjusted enoxaparin and evaluate the incidence of VTE with fixed-dose enoxaparin. Blinded clinical assessments were performed at day 14, and patients randomly assigned to fixed-dose enoxaparin subsequently underwent a bilateral lower extremity ultrasound. A total of 50 patients were enrolled and randomized. The median weight of patients enrolled in weight-adjusted enoxaparin arm was 76 kg (range, 60.9-124.5 kg). There were no major hemorrhages or symptomatic VTE in either arm. At time of completion of the blinded clinical assessment, there was only 1 incidentally identified pulmonary embolus that occurred in the weight-adjusted arm. In the group randomly assigned to fixed-dose enoxaparin who subsequently underwent surveillance ultrasound, the cumulative incidence of DVT was 22% (90% binomial confidence interval, 0%-51.3%). This phase 2 trial confirms a high incidence of asymptomatic VTE among high-risk hospitalized patients with cancer and that weight-adjusted LMWH thromboprophylaxis is feasible and well-tolerated. This trial was registered at www.clinicaltrials.gov as #NCT02706249.
引用
- Zwicker JI, Roopkumar J, Puligandla M, et al. Dose-adjusted enoxaparin thromboprophylaxis in hospitalized cancer patients: a randomized, double-blinded multicenter phase 2 trial. Blood Adv. 2020. PMID: 32442298. doi:10.1182/bloodadvances.2020001804
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。